<div id="readability-page-1"><p>In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Dexcom, with a price target of <span id="expert-recommendation-target">$112.00</span>. The company’s shares closed yesterday at $68.20.</p><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, Dexcom, and Insulet. According to TipRanks, Taylor has an average return of <span>7.2%</span> and a 55.90% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $90.33, a 32.45% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $85.00 price target.</p></div>

DXCM

SBIO

<p>Jefferies analyst Matthew Taylor has maintained a Buy rating on Dexcom (DXCM) with a price target of $112.00, while the stock closed at $68.20. The analyst consensus is a Strong Buy with an average price target of $90.33, indicating a potential upside of 32.45%. BTIG also supports a Buy rating with a target of $85.00. Taylor has an average return of 7.2% and a 55.90% success rate on his recommendations.</p>

Tip Ranks

SPDR S&P Health Equip

DexCom

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

Dexcom (DXCM) Gets a Buy from Jefferies